Presentation is loading. Please wait.

Presentation is loading. Please wait.

UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Oral Contraceptives and CVD Epidemiologic Effects TMM Farley Department of Reproductive.

Published byNickolas Bates Modified over 9 years ago

Similar presentations

Presentation on theme: "UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Oral Contraceptives and CVD Epidemiologic Effects TMM Farley Department of Reproductive."— Presentation transcript:

1 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Oral Contraceptives and CVD Epidemiologic Effects TMM Farley Department of Reproductive Health and Research World Health Organization Geneva

2 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Overview Rationale for WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone ContraceptionRationale for WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Venous thromboembolism, stroke and myocardial infarctionVenous thromboembolism, stroke and myocardial infarction Supplement with data from other recent studiesSupplement with data from other recent studies Overall cardiovascular riskOverall cardiovascular risk

3 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research OC composition and patterns of use have changed since late 1970sOC composition and patterns of use have changed since late 1970s Most information refers to older productsMost information refers to older products No information available on risks in women from developing countriesNo information available on risks in women from developing countries “What are the cardiovascular risks associated with modern OCs used in modern ways?”“What are the cardiovascular risks associated with modern OCs used in modern ways?” WHO Study of Cardiovascular Disease and Steroid Hormone Contraception - 1986

4 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research WHO Study of Cardiovascular Disease and Hormonal Contraception

5 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research WHO CVD Study - Design Hospital-based case-control studyHospital-based case-control study 17 countries (12 developing, 5 in Europe)17 countries (12 developing, 5 in Europe) Conducted February 1989 - January 1993Conducted February 1989 - January 1993 First time cases of stroke, AMI or idiopathic VTE in women aged 20-44 yearsFirst time cases of stroke, AMI or idiopathic VTE in women aged 20-44 years 3 controls per case, matched on age, hospital and time period3 controls per case, matched on age, hospital and time period 2,242 stroke, 368 AMI, 1,143 VTE, 10,025 controls2,242 stroke, 368 AMI, 1,143 VTE, 10,025 controls

6 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Venous Thromboembolism Adjusted odds ratio (95% CI) WHO, Lancet 1995; 346:1575

7 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Risk Factors for Idiopathic VTE Increased relative risk withIncreased relative risk with –OC use –elevated body mass index –hypertension in pregnancy No effect on relative riskNo effect on relative risk –smoking, age, hypertension –duration of OC use –previous OC use WHO, Lancet 1995; 346:1575

8 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research VTE and Low Estrogen OCs Adjusted odds ratios (95% CI) WHO, Lancet 1995; 346:1575

9 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research VTE and Low Estrogen OCs Excess risk with desogestrel & gestodene compared with levonorgestrelExcess risk with desogestrel & gestodene compared with levonorgestrel –About 2.5  higher risk –Similar excess risk for the two products –Bias or confounding unlikely explanation Unexpected, Unexplained, Unwelcome, UncomfortableUnexpected, Unexplained, Unwelcome, Uncomfortable “Must be confirmed by independent research”“Must be confirmed by independent research”

10 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research 3 rd Gen vs. Levonorgestrel Adjusted risks relative to non-users (crude risk) Lancet 1995; 346:1582, 1589, 1593; BMJ 1996; 312: 83; Contraception 1998; 57: 291 Overall risk ratio (95% CI) 1.9 (1.5, 2.2)

11 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Ischaemic Stroke Major risk factorsMajor risk factors –smoking –hypertension –rheumatic heart disease –diabetes Overall risk with OC use 2.9 (2.2 - 3.9)Overall risk with OC use 2.9 (2.2 - 3.9) No effect of past OC use or duration of useNo effect of past OC use or duration of use

12 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Ischaemic Stroke - smoking Pooled adjusted odds ratio (95% CI) [% controls] WHO, Lancet 1996; 348: 498

13 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Ischaemic Stroke - Hypertension Pooled adjusted odds ratio (95% CI) [% controls] WHO, Lancet 1996; 348: 498

14 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Ischaemic Stroke and Low Estrogen OCs Kaiser, CA1.2 (0.5, 2.6)Kaiser, CA1.2 (0.5, 2.6) Washington State1.4 (0.5, 3.8)Washington State1.4 (0.5, 3.8) Denmark1.6 (1.1, 2.4)Denmark1.6 (1.1, 2.4) WHO Europe1.4 (0.6, 3.1) Developing countries3.4 (2.2, 3.1)WHO Europe1.4 (0.6, 3.1) Developing countries3.4 (2.2, 3.1) TransNational2.8 (2.0, 3.8)TransNational2.8 (2.0, 3.8) RR (95% CI) compared with non-users

15 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research With Blood Pressure check WHO Europe1.3 (0.5, 3.5) WHO Developing 2.1 (1.1, 3.8) TransNational2.1 (1.4, 3.1)With Blood Pressure check WHO Europe1.3 (0.5, 3.5) WHO Developing 2.1 (1.1, 3.8) TransNational2.1 (1.4, 3.1) Without Blood Pressure check WHO Europe1.5 (0.5, 4.6) WHO Developing5.2 (2.9, 9.1) TransNational4.5 (2.6, 8.0)Without Blood Pressure check WHO Europe1.5 (0.5, 4.6) WHO Developing5.2 (2.9, 9.1) TransNational4.5 (2.6, 8.0) Ischaemic Stroke and Low Estrogen OCs RR (95% CI) compared with non-users

16 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Ischaemic stroke - Conclusion Some excess risk associated with low estrogen dose OCsSome excess risk associated with low estrogen dose OCs Smoking and hypertension potentiate OC- associated riskSmoking and hypertension potentiate OC- associated risk Lower risk when screened for hypertensionLower risk when screened for hypertension No evidence of difference in risk according to OC type (2 nd vs. 3 rd generation)No evidence of difference in risk according to OC type (2 nd vs. 3 rd generation)

17 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Haemorrhagic Stroke No difference according to BP checkingNo difference according to BP checking No impact on risk in women < 35 yearsNo impact on risk in women < 35 years About 2  risk in women over 35 yearsAbout 2  risk in women over 35 years Higher (relative) risk among older women, smokers, women with h x of hypertensionHigher (relative) risk among older women, smokers, women with h x of hypertension Smoking has greater impact on risk of haemorrhagic than ischaemic strokeSmoking has greater impact on risk of haemorrhagic than ischaemic stroke Consistent with data from Kaiser, CA (Petitti, 1996)Consistent with data from Kaiser, CA (Petitti, 1996)

18 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Myocardial Infarction Major risk factorsMajor risk factors –smoking, hypertension, rheumatic heart disease, diabetes, hyperlipidaemia Overall risk with OC use 4.9 (3.1 - 7.8)Overall risk with OC use 4.9 (3.1 - 7.8) No effect of past OC use or duration of useNo effect of past OC use or duration of use Lower risks with low compared with high dose OCsLower risks with low compared with high dose OCs

19 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research AMI - Hypertension & OC use Pooled adjusted odds ratio (95% CI) [% controls] WHO, Lancet 1997; 349: 1202

20 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research AMI - smoking & OC use Pooled adjusted odds ratio (95% CI) [% controls] WHO, Lancet 1997; 349: 1202

21 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research AMI - Conclusion Majority of cases (78%) occur in smokersMajority of cases (78%) occur in smokers Lower risk with low dose OCs, in women without CV risk factors and who reported BP check (similar observations in TransNational study)Lower risk with low dose OCs, in women without CV risk factors and who reported BP check (similar observations in TransNational study) Among women with no cardiovascular risk factors who do not smoke, RR = 1.1 in women with BP checkAmong women with no cardiovascular risk factors who do not smoke, RR = 1.1 in women with BP check

22 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research AMI and Type of OC Lancet 1997; 349: 1202; Contraception 1997; 56: 129; BMJ 1999; 318: 1579; NEJM 2001; 345: 1787

23 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Overall Cardiovascular Risk Different risk factors for VTE and stroke or MIDifferent risk factors for VTE and stroke or MI Age distribution of VTE, stroke and MI cases very different over 15 - 44 age rangeAge distribution of VTE, stroke and MI cases very different over 15 - 44 age range Any reduction in MI risk for third generation OC users more important for older women and smokersAny reduction in MI risk for third generation OC users more important for older women and smokers

24 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Age group (years) Incidence (per 100 000 wyrs) Observed CVD Incidence Oxford VTE Haemorrhagic stroke Ischaemic stroke AMI J Epidemiol Comm Health 1998; 52: 775

25 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research CVD Incidence - Non-smoker 20-24y30-34y40-44y20-24y30-34y40-44y Events per 10 6 wyrs Non-OC userOC user

26 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research CVD Mortality - Non-smoker Non-OC userOC user 20-24y30-34y40-44y20-24y30-34y40-44y Deaths per 10 6 wyrs

27 UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research OCs and CVD OCs most widely studied pharmacologic agentOCs most widely studied pharmacologic agent In young women without cardiovascular risk factors, OCs are safeIn young women without cardiovascular risk factors, OCs are safe Excess risk seen in older women, smokers and those with pre-existing risk factorsExcess risk seen in older women, smokers and those with pre-existing risk factors Risk-benefit of 2 nd vs. 3 rd generation OCsRisk-benefit of 2 nd vs. 3 rd generation OCs –VTE risk more important in younger women –MI risk more important in older women and smokers

Download ppt "UNDP/UNFPA/WHO/WORLD BANK HRPRHR Reproductive Health and Research Oral Contraceptives and CVD Epidemiologic Effects TMM Farley Department of Reproductive."

Similar presentations

How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.

How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.
The results of the Study of Heart and Renal Protection (SHARP)

The results of the Study of Heart and Renal Protection (SHARP)
WHO CVD Atlas. 2002. WHO Stroke Atlas. 2002. The Burden of CVD in Asia: Stroke Deaths by Country, 2002 2.

WHO CVD Atlas WHO Stroke Atlas The Burden of CVD in Asia: Stroke Deaths by Country,
Does Preoperative Hemoglobin Value Predict Postoperative Cardiovascular Complications after Total Joint Arthroplasty? Kishor Gandhi MD, MPH, Eugene Viscusi.

Does Preoperative Hemoglobin Value Predict Postoperative Cardiovascular Complications after Total Joint Arthroplasty? Kishor Gandhi MD, MPH, Eugene Viscusi.
The results of the Study of Heart and Renal Protection (SHARP) Colin Baigent, Martin Landray on behalf of the SHARP Investigators Disclosure: SHARP was.

The results of the Study of Heart and Renal Protection (SHARP) Colin Baigent, Martin Landray on behalf of the SHARP Investigators Disclosure: SHARP was.
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.

1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.

CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Health risks of smoking Principal fatal diseases caused by smoking are cancer, COPD and CVD In addition, smoking is an important cause of morbidity Risks.

Health risks of smoking Principal fatal diseases caused by smoking are cancer, COPD and CVD In addition, smoking is an important cause of morbidity Risks.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care

Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Understanding real research 3. Assessment of risk.

Understanding real research 3. Assessment of risk.
What women can do to stay healthy Valerie Beral University of Oxford THE MILLION WOMEN STUDY.

What women can do to stay healthy Valerie Beral University of Oxford THE MILLION WOMEN STUDY.
Measures of association

Measures of association
Type 2 diabetes and high blood pressure How explosive is the cocktail?

Type 2 diabetes and high blood pressure How explosive is the cocktail?
Authors: Sujai M. Parker, Gunjan N. Jodi, Jalak Jani

Authors: Sujai M. Parker, Gunjan N. Jodi, Jalak Jani
Combined Oral Contraceptive Pills (COCs)

Combined Oral Contraceptive Pills (COCs)
HEAPHY 1 & 2 DIAGNOSTIC James HAYES Fri 30 th Aug 2013 Session 2 / Talk 4 11:33 – 12:00 ABSTRACT To estimate population attributable risks for modifiable.

HEAPHY 1 & 2 DIAGNOSTIC James HAYES Fri 30 th Aug 2013 Session 2 / Talk 4 11:33 – 12:00 ABSTRACT To estimate population attributable risks for modifiable.
Understanding study designs through examples Manish Chaudhary MPH (BPKIHS)

Understanding study designs through examples Manish Chaudhary MPH (BPKIHS)
P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.

P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.
SYDNEY MEDICAL SCHOOL What do the IST-3 results mean for the elderly patient with acute stroke? Westmead Hospital Clinical School | George Institute for.

SYDNEY MEDICAL SCHOOL What do the IST-3 results mean for the elderly patient with acute stroke? Westmead Hospital Clinical School | George Institute for.

Similar presentations

Ads by Google